News Daily News Little Pre- and Postmarket Testing for Most Recalled CV Devices Michael O'Riordan September 16, 2024
News Daily News Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective Michael O'Riordan February 23, 2024
News Daily News British Medical Groups Express Concern About Inclisiran Rollout Michael O'Riordan December 14, 2021
News Daily News FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl Michael O'Riordan November 14, 2019